Epithelial Ovarian Cancer, Ovarian Cancer, Serous Ovarian Tumor
Conditions
Keywords
Ovarian Cancer, Epithelial Ovarian Cancer, Serous Ovarian Tumor, Isoquercetin, Memorial Sloan Kettering Cancer Center, 25-060
Brief summary
The purpose of this study is to test whether isoquercetin can reduce markers in the blood that may indicate the risk of blood clots in people with ovarian cancer. The effects of isoquercetin will be compared with those of a placebo.
Interventions
DRUGIsoquercetin
Cohort B and Cohort C will take isoquercetin
OTHERPlacebo
Placebo
Sponsors
Memorial Sloan Kettering Cancer Center
National Institutes of Health (NIH)
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Caregiver)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Participants must have histological- or cytological-confirmed ovarian cancer (epithelial, serous, or clear cell) and be receiving first-line chemotherapy (day 1 of isoquercetin should align with day 1 of cycle 1 or 2 of chemotherapy) for neoadjuvant, adjuvant, or advanced settings. * Minimum age 18 years * Life expectancy of greater than 6 months. * ECOG performance status \<2 * Participants must have preserved organ and marrow function as defined below: * Platelet count \> 50,000/mcL * Prothrombin time (PT) and partial thromboplastin time (PTT) \< 1.5 x institutional upper limit of normal (ULN) * Total bilirubin \< 3 x ULN without liver metastases and \<5 x ULN in presence of liver metastases. * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \< 3 X ULN without liver metastases and \<5 x ULN in the presence of liver metastases. * Estimated creatinine clearance (CrCl \>30 ml/min) * The effects of isoquercetin on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. * Ability to understand and the willingness to sign a written informed consent document.
Exclusion criteria
* Prior history of documented venous thromboembolic event within the last 2 years (excluding central line associated events whereby patients completed anticoagulation) * Active bleeding or high risk for bleeding (e.g., known acute gastrointestinal ulcer) * History of significant hemorrhage (requiring hospitalization or transfusion) outside of a surgical setting within the last 24 months * Familial bleeding diathesis * Known diagnosis of disseminated intravascular coagulation (DIC) * Currently receiving anticoagulant therapy * Current daily use of aspirin, clopidogrel (Plavix), cilostazol (Pletal), aspirin-dipyridamole (Aggrenox) (within 10 days) or considered to use regular use of higher doses of non-steroidal anti-inflammatory agents as determined by the treating physician (e.g ibuprofen \> 800 mg daily or equivalent) * Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements * Known intolerance of (iso)quercetin, niacin or ascorbic acid (including known G6PD deficiency). * Participants with known brain metastases * Pregnant women are excluded from this study because isoquercetin is a PDI inhibitor with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk of adverse events in nursing infants secondary to treatment of the mother with isoquercetin, breastfeeding should be discontinued if the mother is treated with isoquercetin.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Level of PDI-sensitive, platelet-dependent thrombin generation measured as compared to baseline | up to 6 weeks from baseline | The primary endpoint is the maximal inhibition of PDI-sensitive, platelet-dependent thrombin generation measured at either 3 or 6 weeks (relative to baseline). |
Countries
United States
Contacts
CONTACTJeffrey Zwicker, MD
CONTACTElizabeth Jewell, MD
PRINCIPAL_INVESTIGATORJeffrey Zwicker, MD
Memorial Sloan Kettering Cancer Center
Outcome results
None listed